This content is in French.
Zanubrutinib: toward a new era in CLL?
27 janvier 2026
By Ana Espino | Published on January 27, 2026 | 3 min readChronic lymphocytic leukemia (CLL) is a malignant hematologic disorder characterized by the slow but progressive accumulation of mature B lymphocytes in the blood, bone marrow, and lymphoid organs. Although often indolent at onset, the disease may evolve into more aggressive forms, with an increased risk of infections, bone marrow failure,
Chronic lymphocytic leukemia (CLL) is a malignant hematologic disorder characterized by the slow but progressive accumulation of mature B lymphocytes in the blood, bone marrow, and lymphoid organs. Although often indolent at onset, the disease may evolve into more aggressive forms, with an increased risk of infections, bone marrow failure, and transformation into high-grade lymphoma.
For several years, standard management has relied on combinations of chemotherapy and monoclonal antibodies, particularly the bendamustine–rituximab (BR) regimen. While effective in the short term, these treatments are associated with significant toxicity, limited tolerability in elderly or frail patients, and reduced efficacy in genetically high-risk disease, such as cases with 17p deletion or TP53 mutation.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Shadman M, et al. Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA. J Clin Oncol. 2025 Mar;43(7):780-787
View the source
